Avadel Pharmaceuticals (FRA:AWK) EPS (Basic) : €-0.48 (TTM As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Avadel Pharmaceuticals EPS (Basic)?

Avadel Pharmaceuticals's basic earnings per share (Basic EPS) for the three months ended in Dec. 2024 was €-0.05. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2024 was €-0.48.

Avadel Pharmaceuticals's EPS (Diluted) for the three months ended in Dec. 2024 was €-0.05. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was €-0.48.

Avadel Pharmaceuticals's EPS without NRI for the three months ended in Dec. 2024 was €-0.06. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2024 was -0.52.

During the past 3 years, the average EPS without NRI Growth Rate was 25.80% per year. During the past 5 years, the average EPS without NRI Growth Rate was -11.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Avadel Pharmaceuticals's highest 3-Year average EPS without NRI Growth Rate was 37.90% per year. The lowest was -86.60% per year. And the median was 10.70% per year.

Avadel Pharmaceuticals EPS (Basic) Historical Data

The historical data trend for Avadel Pharmaceuticals's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avadel Pharmaceuticals EPS (Basic) Chart

Avadel Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

EPS (Basic)

Get a 7-Day Free Trial

0.11

-1.17

-2.16

-1.83

-0.49

Avadel Pharmaceuticals Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
EPS (Basic)	Get a 7-Day Free Trial															-0.27	-0.28	-0.13	-0.03	-0.05

Avadel Pharmaceuticals EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Avadel Pharmaceuticals's Basic EPS for the fiscal year that ended in Dec. 2024 is calculated as

Basic EPS (A: Dec. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-46.635	-	0)	/	95.141
	=	-0.49

Avadel Pharmaceuticals's Basic EPS for the quarter that ended in Dec. 2024 is calculated as

Basic EPS (Q: Dec. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-4.816	-	0)	/	96.404
	=	-0.05

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.48

Avadel Pharmaceuticals (FRA:AWK) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Avadel Pharmaceuticals EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Avadel Pharmaceuticals's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Avadel Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Avadel Pharmaceuticals PLC (FRA:AWK) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

AVDL:USA AWK:Germany

Address

10 Earlsfort Terrace, Dublin 2, Dublin, IRL, D02 T380

Website

https://www.avadel.com

Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.